PHOENIX, AZ--(Marketwired - Sep 4, 2013) - Insys Therapeutics, Inc. (
President and Chief Executive Officer, Michael L. Babich, will present on Thursday, September 12, 2013 at 3:15 p.m. ET. The presentation will be webcast live and available for replay at the Insys website www.insysrx.com.
About Insys Therapeutics, Inc.
Insys Therapeutics, Inc. is a commercial-stage specialty pharmaceutical company that develops and commercializes innovative supportive care products, with a focus on utilizing its proprietary formulation technologies to address the clinical shortcomings of existing commercial pharmaceutical products. The company has two marketed products including Subsys, a proprietary sublingual fentanyl spray for breakthrough pain in opioid-tolerant cancer patients. Insys markets Subsys through its incentive-based, cost-efficient commercial sales force. The company's lead product candidate is Dronabinol Oral Solution, a proprietary orally administered liquid formulation of dronabinol, which would be its second branded supportive care product, if approved.